CoChat

Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

Young, Paul W., Buckle, Derek R., Cantello, Barrie C.C., Chapman, Helen, Clapham, John C., Coyle, Paul J., Haigh, David, Hindley, Richard M., Holder, Julie C., Kallender, Howard, Latter, Alison J., Lawrie, Kenneth W.M., Mossakowska, Danuta, Murphy, Gregory J., Cox, Lynne Roxbee, Smith, Stephen A. · 1998 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 101

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

A radioiodinated ligand, [I]SB-236636 [(S)-(2)3-[4-[2-[N-(2benzoxazolyl)-N-methylamino]ethoxy]3-[I]iodophenyl]2-ethoxy propanoic acid], which is specific for the g isoform of the peroxisomal proliferator activated receptor (PPARg), was developed. [I]SB-236636 binds with high affinity to full-length human recombinant PPARg1 and to a GST (glutathione Stransferase) fusion protein containing the ligand binding domain of human PPARg1 (KD 5 70 nM). Using this ligand, we characterized binding sites in adipose-derived cells from rat, mouse and humans. In competition experiments, rosiglitazone (BRL-49653), a potent antihyperglycemic agent, binds with high affinity to sites in intact adipocytes (IC50 5 12, 4 and 9 nM for rat, 3T3-L1 and human adipocytes, respectively). Binding affinities (IC50) of other thiazolidinediones for the ligand binding domain of PPARg1 were comparable with those determined in adipocytes and reflected the rank order of potencies of these agents as stimulants of glucose transport in 3T3-L1 adipocytes and antihyperglycemic agents in vivo: rosiglitazone . pioglitazone . troglitazone. Competition of [I]SB-236636 binding was stereoselective in that the IC50 value of SB-219994, the (S)-enantiomer of an a-trifluoroethoxy propanoic acid insulin sensitizer, was 770-fold lower than that of SB-219993 [(R)enantiomer] at recombinant human PPARg1. The higher binding affinity of SB-219994 also was evident in intact adipocytes and reflected its 100-fold greater potency as an antidiabetic agent. The results strongly suggest that the high-affinity binding site for [I]SB-236636 in intact adipocytes is PPARg and that the pharmacology of insulin-sensitizer binding in rodent and human adipocytes is very similar and, moreover, predictive of antihyperglycemic activity in vivo. Thiazolidinedione insulin sensitizers are a new class of antihyperglycemic agent that after chronic administration to animal models of non–insulin-dependent diabetes, improve glycemic control by enhancing insulin action in target tissues rather than by increasing insulin secretion. Numerous studies using a number of thiazolidinediones indicate that these agents enhance insulin-mediated suppression of hepatic glucose production and promote insulin-stimulated glucose transport into skeletal muscle and adipose tissue (Hulin et al., 1996). Increased glucose disposal, in adipose tissue at least, results from a combination of increased expression of GLUT-4 and increased translocation of GLUT-4 to the adipocyte cell surface in response to insulin (Young et al., 1995). In addition to improving insulin action in diabetic animal models, thiazolidinediones can influence adipocyte function in vitro. They increase glucose transport in differentiated 3T3-L1 adipocytes in culture, an action mediated by an insulin-independent increase in the expression of glucose transporters (Gibbs et al., 1989), and they can stimulate preadipocyte differentiation and expression of adipose-specific genes (Ibrahimi et al., 1994; Kletzien et al., 1992). The relevance of actions in adipose cells is underscored by the finding that the rank order of potency of thiazolidinediones as antidiabetic agents in vivo is highly correlated with their potencies as adipogenic stimulants in vitro (Lenhard et al., 1996). Received for publication June 17, 1997. ABBREVIATIONS: PPAR, peroxisomal proliferator-activated receptor; hPPAR, human peroxisomal proliferator-activated receptor; mPPAR, murine peroxisomal proliferator-activated receptor; GLUT-4, glucose transporter isoform 4; GST, glutathione S-transferase; AEBSF, 4-(2aminoethyl)benzenesulfenylfluoride hydrochloride; ETYA, 5,8,11,14-eicosatetraynoic acid; HETE, 8-hydroxyeicosatetraenoic acid; PCR, polymerase chain reaction; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; DMSO, dimethylsulfoxide; BSA, bovine serum albumin; DPBS, Dulbecco’s phosphate-buffered saline; DMEM, Dulbecco’s modified Eagle’s medium; LBD, ligand binding domain. 0022-3565/98/2842-0751$03.00/0 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 284, No. 2 Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics Printed in U.S.A. JPET 284:751–759, 1998 751 at A PE T Jornals on A uust 9, 2017 jpet.asjournals.org D ow nladed from Rosiglitazone (BRL-49653), a potent thiazolidinedione insulin sensitizer, has recently been identified as a high-affinity ligand for PPARg, a nuclear hormone receptor that is abundantly expressed in adipocytes and plays a central role as a regulator of terminal adipocyte differentiation (Lehmann et al., 1995; Tontonez et al., 1994). Two splice variants of PPARg have been identified. Human and murine PPARg1 and PPARg2 bind rosiglitazone with comparable affinities, and both g subtypes are activated equally by the compound in transactivation assays (Elbrecht et al., 1996). The activation of another PPAR isoform, PPARd (also known as fatty acid-activated receptor, or NUC-1), by high concentrations of rosiglitazone has been reported by some (Ibrahimi et al., 1994) but not all (Lehmann et al., 1995) researchers, and the relative contributions of activation of PPARd and PPARg to the adipogenic response to thiazolidinediones remain controversial. The implication that one or more PPARs play a key role in the antidiabetic mechanism of thiazolidinediones has arisen entirely from correlations of compound potencies in animal models with potencies/affinities determined in binding and functional studies using recombinant PPAR isoforms (Willson et al., 1996). Direct evidence for the existence of specific binding sites for insulin sensitizers in normal rodentand human-derived cells is lacking. In this report, to identify specific binding sites in intact rodent and human adipocytes, we describe the use of a high-specific-activity radioiodinated ligand, [I]SB-236636, that binds with high affinity and specificity to the LBD of recombinant hPPARg1. The properties of these binding sites, assessed with a variety of PPAR subtype-selective ligands, are comparable in rat and human adipocytes and highly correlated with the pharmacology of binding to recombinant PPARg1. Materials and Methods All cell culture reagents were purchased from GIBCO (Paisley, Scotland, UK). 2-Deoxy-D-[2,6-H]glucose was purchased from Amersham International (Berkshire, UK). SB-217092 [(6)-3-[4-[2-[N-(2benzoxazolyl)-N-methylamino]ethoxy]3-iodophenyl]2-ethoxypropanoic acid], [I]SB-236636 [(S)-(2)-3-[4-[2-[N-(2-benzoxazoyl)-Nmethylamino]ethoxy]3-[]iodophenyl]2-ethoxypropanoic acid; 2500 Ci/mmol], rosiglitazone (BRL-49653) [(6)-5-[[4-[2-[N-methyl-N-(2pyridyl)amino]ethoxy]phenyl]methyl]2,4-thiazolidinedione], SB219993 [(R)-(1)-3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]2-(2,2,2-trifluoroethoxy)propanoic acid], SB-219994 [(S)-(2)3-[4-[2-[N-(2-benzoxazolyl)-N-methylamino]ethoxy]phenyl]2-(2,2,2trifluoroethoxy) propanoic acid], pioglitazone and troglitazone were synthesized in-house (fig. 1). Collagenase (136–169 U/mg CLS1) was obtained from Lorne Laboratories (Reading, UK), and bovine serum albumin (fraction V) was purchased from Boehringer-Mannheim (Sussex, UK). AEBSF was purchased from Calbiochem (Nottingham, UK). LY 171883, Wy 14643 and ETYA were purchased from BIOMOL Research Laboratories (Plymouth Meeting, PA). 2-Bromopalmitic acid was purchased from Aldrich (Gillingham, Dorset, UK), and 15-deoxy-D-prostaglandin J2 was obtained from Cayman Chemical (Ann Arbor, MI). HAWP 02500 (0.45-mm) filters were obtained from Millipore (Watford, UK). All other chemicals were Fig. 1. Structures of insulin sensitizers. Full chemical names of novel structures are given in the text. 752 Young et al. Vol. 284 at A PE T Jornals on A uust 9, 2017 jpet.asjournals.org D ow nladed from purchased from Sigma (Poole, Dorset, UK). Kits for the estimation of glucose were obtained from Ciba-Corning, Halstead, Essex, UK. The 3T3-L1 fibroblast cell line was obtained from American Type Culture Collection (Rockville, MD).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(24)37268-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 101

Metadata

Authors
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., Latter, A. J., Lawrie, K. W. M., Mossakowska, D., Murphy, G. J., Cox, L. R., & Smith, S. A.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
1998-02
Volume
284
Issue
2
Pages
751-759
ISSN
0022-3565 (ISSN-L)
OpenAlex
W4406057004
Cited by
101
References
2
FWCI
1.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ. https://app.cochat.ai/papers/10.1016/s0022-3565(24)37268-4
The paper
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., Latter, A. J., Lawrie, K. W. M., Mossakowska, D., Murphy, G. J., Cox, L. R., & Smith, S. A. (1998). Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)37268-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.